Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Depreciation & Amortization (CF): 2010-2025

Historic Depreciation & Amortization (CF) for Northwest Biotherapeutics (NWBO) over the last 15 years, with Sep 2025 value amounting to $451,000.

  • Northwest Biotherapeutics' Depreciation & Amortization (CF) rose 1.35% to $451,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 2.43%. This contributed to the annual value of $1.7 million for FY2024, which is 14.36% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Depreciation & Amortization (CF) stood at $451,000 for Q3 2025, which was down 0.00% from $451,000 recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Depreciation & Amortization (CF) peaked at $524,000 during Q2 2022, and registered a low of $68,000 during Q1 2021.
  • In the last 3 years, Northwest Biotherapeutics' Depreciation & Amortization (CF) had a median value of $434,000 in 2025 and averaged $418,636.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Depreciation & Amortization (CF) soared by 3,750.00% in 2021, and later plummeted by 33.21% in 2023.
  • Over the past 5 years, Northwest Biotherapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $84,000 in 2021, then skyrocketed by 278.57% to $318,000 in 2022, then skyrocketed by 33.33% to $424,000 in 2023, then rose by 3.07% to $437,000 in 2024, then increased by 1.35% to $451,000 in 2025.
  • Its Depreciation & Amortization (CF) stands at $451,000 for Q3 2025, versus $451,000 for Q2 2025 and $434,000 for Q1 2025.